Get access

Interferon in the treatment of cutaneous T-cell lymphoma

Authors


Address correspondence and reprint requests to: Elise A. Olsen, Professor of Medicine, Division of Dermatology, Box 3294, DUMC, Durham, NC 27710, or email: olsen001@mc.duke.edu.

Abstract

ABSTRACT:  Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T-cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side-effects are predictable, generally well tolerated and dose-related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side-effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.

Ancillary